# US 6,727,058 B2 · Intergrase assay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,058 B2
- Document ID: US6727058B2
- Status: Granted
- Kind: B2
- Application number: 09/803,863
- Filed: 2001-03-12
- Published: 2001-07-26
- Granted: 2004-04-27
- Earliest claimed: 1998-03-18
- Assignees: The Salk Institute for Biological Studies
- Inventors: Frederic Bushman; Mark Hansen
- Web page: https://patentgrep.com/patent/US6727058B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides packaging cell lines and recombinant lentiviral or retroviral particles produced therefrom, particularly pseudotyped retroviral particles. The packaging cell lines of the invention are produced by inducibly expressing an envelope protein by methods described herein. Also described is a screening assay for compounds that affect integration of viral nucleic acid into target (e.g., host) nucleic acid. Such compounds are identified based on their effect on viral integrase.

## Claims

### Claim 1

A method of detecting a viral nucleic acid sequence integrated into a target nucleic acid sequence comprising:
a) immobilizing a target nucleic acid sequence to a solid support;
b) contacting the target nucleic acid with a viral preintegration complex (PIC) containing a viral nucleic acid sequence, under conditions sufficient to allow the viral nucleic acid sequence to integrate into the target nucleic acid sequence;
c) releasing the immobilized target nucleic acid sequence; and
d) detecting the integrated viral nucleic acid sequence in the released target nucleic acid sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein the viral preintegration complex (PIC) is isolated from HIV-infected cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein integration of the viral nucleic acid sequence in the target nucleic acid is detected using a polymerase chain reaction.

### Claim 4 (depends on 1)

The method of claim 1, wherein integration of the viral nucleic acid sequence in the target nucleic acid is detected by nucleic acid probe hybridization under stringent conditions.

### Claim 5 (depends on 1)

The method of claim 1, wherein the viral preintegration complex (PIC) is isolated from HIV vector infected cells.

### Claim 6 (depends on 1)

The method of claim 1, further comprising quantifying the viral nucleic acid sequence in the released target nucleic acid sequence.

### Claim 7

A method of identifying a compound that modulates viral integrase activity contained in a preintegration complex (PIC) comprising:
a) immobilizing a target nucleic acid sequence to a solid support;
b) contacting the target nucleic acid of a) with a viral preintegration complex (PIC) containing a viral nucleic acid sequence, under such conditions and for sufficient time so as to allow the viral nucleic acid sequence to integrate into the target nucleic acid sequence;
c) contacting the preintegration complex with a compound suspected of modulating integrase activity prior to, or simultaneously with, b);
d) releasing the immobilized target nucleic acid sequence; and
e) detecting the integrated viral nucleic acid sequence;
wherein the amount of viral nucleic acid sequence integrated in the released target nucleic acid sequence is indicative of the effect of the compound on integrase activity.

### Claim 8 (depends on 7)

The method of claim 7, wherein the effect of the compound on integrase activity is inhibition.

### Claim 9 (depends on 7)

The method of claim 7, wherein the viral integrase activity is HIV integrase.

### Claim 10 (depends on 7)

The method of claim 7, wherein integration of the viral nucleic acid sequence in the target nucleic acid is detected using a polymerase chain reaction.

### Claim 11 (depends on 7)

The method of claim 7, wherein integration of the viral nucleic acid sequence in the target nucleic acid is detected by nucleic acid probe hybridization under stringent conditions.

### Claim 12 (depends on 7)

The method of claim 7, wherein the viral preintegration complex (PIC) is isolated from HIV vector infected cells.

### Claim 13 (depends on 7)

The method of claim 7, further comprising quantifying the viral nucleic acid sequence in the released target nucleic acid sequence.
